SCHEMBL5346262

SCHEMBL5346262

N#Cc1cccc(NC(=O)N2CCC(CN3CCC(Cc4ccccc4)CC3)CC2)c1

nearest known ligand 0.70

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 15/20 0.70
HTR2A P28223 1/20 0.65
FAAH O00519 3/20 0.64
CCR2 P41597 1/20 0.60
MGLL Q99685 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7813834 0.91 CCR3 (0.72) CCR3HTR2AFAAH
SCHEMBL5358819 0.86 FAAH (0.85) CCR3FAAH
SCHEMBL7829233 0.86 CCR3 (0.73) CCR3HTR2ACCR2
SCHEMBL7813837 0.84 FAAH (0.61) CCR3HTR2AFAAHMGLL
SCHEMBL4577506 0.84 CCR3 (0.68) CCR3HTR2AFAAHMGLL
SCHEMBL4577305 0.84 CCR3 (0.74) CCR3HTR2A
SCHEMBL5359294 0.82 CCR3 (1.00) CCR3HTR2AFAAH
SCHEMBL1172481 0.82 FAAH (0.77) CCR3FAAHMGLL
SCHEMBL7825964 0.82 CCR3 (0.75) CCR3HTR2ACCR2
SCHEMBL6701753 0.82 CCR3 (1.00) CCR3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299057-A9 HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY KO SOO S 2007-12-27 US claimed
US-7312222-B2 Heterocyclic piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-25 US claimed
US-20040186097-A1 Heterocyclic piperidines as modulators of chemokine receptor activity KO SOO S (US) 2004-09-23 US claimed
US-20020119980-A1 Heterocyclic piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-08-29 US claimed
EP-1140834-A1 HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-10-10 EP claimed
WO-2000035877-A1 HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO claimed
US-20070299057-A9 HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY KO SOO S 2007-12-27 US disclosed
US-7312222-B2 Heterocyclic piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-25 US disclosed
US-7169446-B2 Oxetane compound, actinic ray curable composition, ink composition for ink jet recording, and image formation method KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-01-30 US disclosed
EP-1486526-B1 Oxetane compound, actinic ray curable composition, ink composition for ink jet recording, and image formation method KONICA MINOLTA MED & GRAPHIC (JP) 2006-08-16 EP disclosed
US-20040252171-A1 Oxetane compound, actinic ray curable composition, ink composition for ink jet recording, and image formation method KONICA MINOLTA MEDICAL & GRAPHIC, INC. 2004-12-16 US disclosed
EP-1486526-A1 Oxetane compound, actinic ray curable composition, ink composition for ink jet recording, and image formation method Konica Minolta Medical & Graphic, Inc. (JP) 2004-12-15 EP disclosed
EP-1484370-A1 Photocurable ink, and image recording apparatus and image recording method employing the photocurable ink Konica Minolta Medical & Graphic, Inc. (JP) 2004-12-08 EP disclosed
US-20040241578-A1 Photocurable ink, and image recording apparatus and image recording method employing the photocurable ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2004-12-02 US disclosed
US-20040186097-A1 Heterocyclic piperidines as modulators of chemokine receptor activity KO SOO S (US) 2004-09-23 US disclosed
US-6759411-B2 ANTIHISTAMINES, ANTIALLERGENS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-07-06 US disclosed
US-20020119980-A1 Heterocyclic piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-08-29 US disclosed
US-6331545-B1 TREATING ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, AND INFLAMMATORY BOWEL DISEASES BRISTOL-MYERS SQUIBB PHARMA COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186097-A1 Heterocyclic piperidines as modulators of chemokine receptor activity CCR3, CCR1, CCR4 CCR3 1/4885HTR2A 2011/4885FAAH 861/4885
US-20020119980-A1 Heterocyclic piperidines as modulators of chemokine receptor activity CCR3, CCR1, CCR4 CCR3 1/4885HTR2A 2011/4885FAAH 861/4885
US-20070299057-A9 HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR3, CCR1, CCR4 CCR3 1/4885HTR2A 2077/4885FAAH 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.